Qualitative Platelet Disorders Treatment Market size was over USD 3.26 Billion in 2023 and is expected to cross USD 9.77 Billion by the end of 2036, witnessing more than 8.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of qualitative platelet disorders treatment is estimated at USD 3.52 Billion. The growth of the market can be attributed to the rising medical research activities. The necessity for medical research has increased as a result of the rising need for novel remedies. For instance, the diagnosis of qualitative platelet diseases, which were formerly underdiagnosed or incorrectly recognized, has grown with developments in medical research and technology. This has increased the need for these illnesses' diagnosis and treatment, which is expected to add to the market growth. India's clinical trials market accounted for around 8% of worldwide clinical research activity in 2020.
In addition to these, factors that are believed to fuel the market growth of qualitative platelet disorders treatment include the increasing development of new therapies and treatments. Further, infections such as dengue fever and malaria which are more common in some parts of the Middle East & Africa can induce platelet dysfunction, this as a result is anticipated to boost the market growth during the forecast period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
8.8% |
|
Base Year Market Size (2023) |
USD 3.26 Billion |
|
Forecast Year Market Size (2036) |
USD 9.77 Billion |
|
Regional Scope |
|
Treatment (Platelet Transfusion, Hormonal Therapy, Anti-fibrinolytic Medications, Genetic Counselling)
The global qualitative platelet disorders treatment market is segmented and analyzed for demand and supply by treatment into platelet transfusion, hormonal therapy, anti-fibrinolytic medications, genetic counseling, and others. Out of the five types of treatment, the genetic counseling segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of genetic disorders. The increasing number of genetic disorders across the globe has resulted in a growing demand for genetic counseling services. Individuals and families afflicted by these illnesses can receive advice and help from genetic counselors. For instance, those with a qualitative platelet abnormality, as well as their family members, are advised to seek genetic counseling. In addition, the purpose of genetic counseling is to assist people and families in better comprehending the inheritance pattern of the condition, the dangers to their children, and the many diagnostic and treatment choices. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years. According to the World Health Organization (WHO), in developed nations, genetic illnesses and congenital anomalies account for up to 30% of pediatric hospital admissions, affect 2% to 5% of all live births, and account for roughly 50% of all infant fatalities.
End-user (Hospital, Ambulatory Surgical Center, Specialty Clinics)
The global qualitative platelet disorders treatment market is also segmented and analyzed for demand and supply by end-user into hospitals, ambulatory surgical centers, specialty clinics, and others. Amongst these four segments, the specialty clinics segment is expected to garner a significant share. Accurately identifying and categorizing various forms of qualitative platelet diseases requires the use of cutting-edge diagnostic procedures, which are used in specialty clinics. Moreover, this can aid in choosing the optimal course of action and care alternatives for each patient. In addition, patients with qualitative platelet abnormalities have access to a variety of therapy, including prescription drugs, blood transfusion diagnostics, and other treatments, at specialty clinics. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment |
|
|
By End User |
|
North American Market Forecast
The North American qualitative platelet disorders treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the growing pharmaceutical sector. For instance, the pharmaceutical industry in the region has experienced fast growth as a result of the creation of several new products and treatments for a variety of illnesses, including platelet abnormalities. In addition, several innovative medications and therapies are being explored to address platelet problems. Further, gene therapy strategies that try to address genetic abnormalities leading to platelet problems are also being investigated, which as a result are also anticipated to contribute to the market growth in this region. More than 20% of the world's pharmaceutical manufacturing and over 40% of the market are both based in the US.
Middle East & Africa Forecast
The Middle East & Africa qualitative platelet disorders treatment market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the increasing frequency of qualitative platelet disorders. For instance, QPD is a genetic disease, which is why, it is more common in communities that practice intermarriage. Qualitative platelet disorders are often caused by genetic mutations, and some of these mutations may be more common in certain populations. For instance, the prevalence of Glanzmann thrombasthenia, a rare inherited platelet disorder, is found to be higher in populations with consanguineous marriages, which are more common in some parts of the Middle East & Africa, as a result, anticipated to boost the market growth during the forecast period
Sanofi-aventis Groupe acquired Provention Bio, Inc., to provide best-in-class medications, and to provide those at risk of developing Stage 3 type 1 diabetes with life-changing advantages. Further, the acquisition also advances the company's strategy to move towards pharmaceuticals with distinctive profiles.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?